CPRX EBITDA Growth
Catalyst Pharmaceuticals Inc · EBITDA Growth
CPRX EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported12.95%period ending
CPRX TTM EBITDA YoY % (-434.47% → 12.95%)
Year-over-year change
High-resolution chart · PNG
CPRX ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 12.9547% | |
| 26.5123% | |
| 43.024% | |
| 137.5648% | |
| 142.317% | |
| 98.9997% | |
| 114.5955% | |
| -19.0932% | |
| -7.641% | |
| 20.4789% | |
| 23.7717% | |
| 121.6297% | |
| 119.2669% | |
| 100.7617% | |
| 75.3369% | |
| 57.3693% | |
| 46.3542% | |
| 25.2732% | |
| 16.3383% | |
| 4.388% | |
| -7.7479% | |
| 27.8038% | |
| 323.6729% | |
| 452.4085% | |
| 247.5489% | |
| 193.4982% | |
| 138.0095% | |
| 43.0339% | |
| -52.3481% | |
| -89.2095% | |
| -48.3929% | |
| -29.0682% | |
| -12.2423% | |
| 3.3519% | |
| 17.2604% | |
| 23.1142% | |
| 20.5415% | |
| 5.3216% | |
| -16.3377% | |
| -28.8234% | |
| -45.3481% | |
| -39.8152% | |
| -36.5984% | |
| -38.7928% | |
| -26.9046% | |
| -41.5551% | |
| -46.196% | |
| -74.2736% | |
| -117.9398% | |
| -97.4794% | |
| -58.5381% | |
| -27.8835% | |
| 5.7739% | |
| 13.7276% | |
| -21.0086% | |
| -23.4525% | |
| -31.8026% | |
| -51.0415% | |
| -6.8362% | |
| 6.2451% | |
| 14.9407% | |
| 44.8123% | |
| 55.0434% | |
| 58.0575% | |
| 56.8841% | |
| 33.2931% | |
| -20.1277% | |
| -83.7057% | |
| -132.8277% | |
| -116.731% | |
| -72.5051% | |
| -21.3276% | |
| -28.3484% | |
| -71.9244% | |
| -42.026% | |
| -128.6684% | |
| -59.3772% | |
| -1.0284% | |
| -97.3602% | |
| -41.6138% | |
| -140.0087% | |
| -434.4741% |